Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals is the dominant company in cystic fibrosis (CF) treatment, having developed the only approved drugs that treat the underlying cause of CF rather than its symptoms. Trikafta (elexacaftor/tezacaftor/ivacaftor) treats ~90% of CF patients and has transformed the disease from fatal in childhood to manageable throughout adulthood. Vertex is expanding beyond CF into other rare diseases: pain (non-opioid), kidney disease (APOL1-mediated), and gene editing (Casgevy, the first approved CRISPR therapy).
How Vertex Pharmaceuticals Makes Money
Vertex earns almost entirely from its CF franchise: Trikafta/Kaftrio (~$10B+ annually), with legacy modulators Kalydeco and Symdeko adding ~$2B. The company has essentially no competition in CF drug treatments — its modulator pipeline and IP create a multi-decade moat. Casgevy (with CRISPR Therapeutics) is approved for sickle cell disease and beta-thalassemia and represents Vertex's expansion beyond CF into gene therapy.
Vertex Pharmaceuticals Revenue & Profitability Breakdown
This chart shows how Vertex Pharmaceuticals's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
Vertex Pharmaceuticals Inc. trades at a trailing P/E of 31.55x, generates $2.63B in free cash flow, runs a debt/equity ratio of 9.77, and converts shareholder equity into profit at a 23.5% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
28 analysts covering Vertex Pharmaceuticals Inc. currently lean toward a Buy rating, with a mean 12-month price target of $563.12 (+10.8% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Intrinsic Value Estimates for VRTX
We use 1 valuation model to estimate VRTX's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.
Technical Price Signals
VRTX is currently in a golden cross pattern, trading above its 50-day average of $502.41 and above its 200-day average of $463.80. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
VRTX Investment Case: Bull vs Bear
VRTX's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- Trikafta's clinical benefit is transformative — patients' lung function improves dramatically, and early treatment of children may prevent lung damage entirely, expanding the treatment population.
- Next-generation CF drugs (triple combination, once-daily formulations) maintain patent lifecycle and pricing power well into the 2030s.
- Pain drug (suzetrigine/VX-548) could be the first new non-opioid pain mechanism in decades — a massive market if approved and commercialized successfully.
- Vertex trades at a premium but with essentially zero competition in CF, very high margins (FCF margins of 35%+), and multiple pipeline shots on goal.
Bear Case (Key Risks)
- CF is a finite patient population (~88,000 globally eligible for Trikafta) — growth will eventually slow as the addressable market is fully penetrated.
- Pipeline expansion bets (pain, kidney, gene therapy) are high-risk, high-reward; any clinical failures concentrate risk on the CF moat business.
- Drug pricing pressure under the Inflation Reduction Act could force Vertex to negotiate CF drug prices, reducing long-term revenue per patient.
- Gene therapy (Casgevy) adoption has been very slow due to high cost (~$2.2M per treatment), complicated administration, and limited clinical infrastructure.
What to Watch: VRTX Key Metrics
VRTX Stock — Frequently Asked Questions
Compare VRTX with Peers
VRTX — Related Investment Themes
Unlock the Full VRTX Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.